Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Jaguar Health reduced debt, extended credit, and advanced crofelemer development with non-dilutive funding efforts.
Jaguar Health has improved its financial health by restructuring debt and royalty obligations with Chicago Venture Partners affiliates, reducing $3 million in liabilities, extending a $7 million credit line by three years, and eliminating 48,212 warrants.
No debt from these affiliates matures before July 2026, easing near-term pressure.
The company continues advancing its crofelemer development program for rare gastrointestinal disorders, with sustainable harvesting managed by Napo Pharmaceuticals under fair trade practices.
Jaguar is pursuing non-dilutive funding through potential partnerships and expects clinical milestones in its intestinal failure program.
Forward-looking statements are subject to risks.
Jaguar Health redujo la deuda, extendió el crédito y avanzó el desarrollo de crofelemer con esfuerzos de financiación no dilutivos.